SK9996A3 - Vaccine preparations - Google Patents

Vaccine preparations Download PDF

Info

Publication number: SK9996A3
Authority: SK; Slovakia
Prior art keywords: dna; dna construct; protein; fusion protein; bacterium
Prior art date: 1994-01-31

Application number

SK99-96A

Other languages

English (en)

Slovak (sk)

Inventor

Mohammed A Khan

Carlos E Hormaeche

Steven N Chatfield

Gordon Dougan

Original Assignee

Medeva Holdings Bv

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1994-01-31

Filing date

1994-07-29

Publication date

1996-09-04

1994-07-29 Application filed by Medeva Holdings Bv filed Critical Medeva Holdings Bv

1994-07-29 Priority claimed from PCT/GB1994/001647 external-priority patent/WO1995004151A2/en

1996-09-04 Publication of SK9996A3 publication Critical patent/SK9996A3/sk

Links

229960005486 vaccine Drugs 0.000 title claims abstract description 18
238000002360 preparation method Methods 0.000 title description 8
108020004414 DNA Proteins 0.000 claims abstract description 47
102000037865 fusion proteins Human genes 0.000 claims abstract description 44
108020001507 fusion proteins Proteins 0.000 claims abstract description 44
241000894006 Bacteria Species 0.000 claims abstract description 41
108090000623 proteins and genes Proteins 0.000 claims abstract description 39
102000004169 proteins and genes Human genes 0.000 claims abstract description 25
230000002238 attenuated effect Effects 0.000 claims abstract description 21
108091028043 Nucleic acid sequence Proteins 0.000 claims abstract description 15
150000001413 amino acids Chemical class 0.000 claims abstract description 11
239000013604 expression vector Substances 0.000 claims abstract description 11
108010055044 Tetanus Toxin Proteins 0.000 claims abstract description 8
239000000203 mixture Substances 0.000 claims abstract description 8
229940118376 tetanus toxin Drugs 0.000 claims abstract description 8
KZNQNBZMBZJQJO-YFKPBYRVSA-N glyclproline Chemical compound NCC(=O)N1CCC[C@H]1C(O)=O KZNQNBZMBZJQJO-YFKPBYRVSA-N 0.000 claims abstract description 3
102100023541 Glutathione S-transferase omega-1 Human genes 0.000 claims description 18
241000242680 Schistosoma mansoni Species 0.000 claims description 10
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 9
238000000034 method Methods 0.000 claims description 7
239000004471 Glycine Substances 0.000 claims description 5
241000700605 Viruses Species 0.000 claims description 4
230000000890 antigenic effect Effects 0.000 claims description 4
244000045947 parasite Species 0.000 claims description 4
XFTWUNOVBCHBJR-UHFFFAOYSA-N Aspergillomarasmine A Chemical group OC(=O)C(N)CNC(C(O)=O)CNC(C(O)=O)CC(O)=O XFTWUNOVBCHBJR-UHFFFAOYSA-N 0.000 claims description 3
239000003937 drug carrier Substances 0.000 claims description 3
108091008146 restriction endonucleases Proteins 0.000 claims description 3
230000001131 transforming effect Effects 0.000 claims description 3
241000233866 Fungi Species 0.000 claims description 2
240000004808 Saccharomyces cerevisiae Species 0.000 claims description 2
238000003776 cleavage reaction Methods 0.000 claims description 2
230000007017 scission Effects 0.000 claims description 2
230000003053 immunization Effects 0.000 claims 2
239000013611 chromosomal DNA Substances 0.000 claims 1
239000012634 fragment Substances 0.000 abstract description 12
KZNQNBZMBZJQJO-UHFFFAOYSA-N N-glycyl-L-proline Natural products NCC(=O)N1CCCC1C(O)=O KZNQNBZMBZJQJO-UHFFFAOYSA-N 0.000 abstract 1
108010077515 glycylproline Proteins 0.000 abstract 1
RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 26
239000013612 plasmid Substances 0.000 description 26
102000036639 antigens Human genes 0.000 description 17
108091007433 antigens Proteins 0.000 description 17
230000004927 fusion Effects 0.000 description 17
239000000427 antigen Substances 0.000 description 16
101100404144 Bacillus subtilis (strain 168) nasD gene Proteins 0.000 description 15
230000014509 gene expression Effects 0.000 description 15
101150044129 nirB gene Proteins 0.000 description 15
210000004027 cell Anatomy 0.000 description 14
108010024636 Glutathione Proteins 0.000 description 13
229960003180 glutathione Drugs 0.000 description 13
108020004707 nucleic acids Proteins 0.000 description 12
102000039446 nucleic acids Human genes 0.000 description 12
150000007523 nucleic acids Chemical class 0.000 description 12
239000013615 primer Substances 0.000 description 11
239000013598 vector Substances 0.000 description 11
241000588724 Escherichia coli Species 0.000 description 10
241000293869 Salmonella enterica subsp. enterica serovar Typhimurium Species 0.000 description 9
239000003795 chemical substances by application Substances 0.000 description 8
238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 8
238000001262 western blot Methods 0.000 description 8
230000001580 bacterial effect Effects 0.000 description 7
229920000936 Agarose Polymers 0.000 description 6
101710101517 Gluconate operon transcriptional repressor Proteins 0.000 description 6
102000005720 Glutathione transferase Human genes 0.000 description 6
108010070675 Glutathione transferase Proteins 0.000 description 6
239000011159 matrix material Substances 0.000 description 6
108020004705 Codon Proteins 0.000 description 5
ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 5
238000006243 chemical reaction Methods 0.000 description 5
238000010276 construction Methods 0.000 description 5
238000001261 affinity purification Methods 0.000 description 4
239000000499 gel Substances 0.000 description 4
230000002163 immunogen Effects 0.000 description 4
108090000765 processed proteins & peptides Proteins 0.000 description 4
239000000047 product Substances 0.000 description 4
230000009466 transformation Effects 0.000 description 4
238000013519 translation Methods 0.000 description 4
FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 3
108091026890 Coding region Proteins 0.000 description 3
241000710198 Foot-and-mouth disease virus Species 0.000 description 3
241000725303 Human immunodeficiency virus Species 0.000 description 3
241000701806 Human papillomavirus Species 0.000 description 3
ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 3
241000283973 Oryctolagus cuniculus Species 0.000 description 3
241000607142 Salmonella Species 0.000 description 3
239000002253 acid Substances 0.000 description 3
150000007513 acids Chemical class 0.000 description 3
AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 3
229960000723 ampicillin Drugs 0.000 description 3
230000003321 amplification Effects 0.000 description 3
239000011324 bead Substances 0.000 description 3
239000002775 capsule Substances 0.000 description 3
LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 3
230000000694 effects Effects 0.000 description 3
238000005516 engineering process Methods 0.000 description 3
239000002609 medium Substances 0.000 description 3
239000006225 natural substrate Substances 0.000 description 3
238000003199 nucleic acid amplification method Methods 0.000 description 3
239000002953 phosphate buffered saline Substances 0.000 description 3
239000007858 starting material Substances 0.000 description 3
239000003053 toxin Substances 0.000 description 3
231100000765 toxin Toxicity 0.000 description 3
241000588832 Bordetella pertussis Species 0.000 description 2
102100029173 Choline-phosphate cytidylyltransferase B Human genes 0.000 description 2
101710100756 Choline-phosphate cytidylyltransferase B Proteins 0.000 description 2
102000053602 DNA Human genes 0.000 description 2
102000004190 Enzymes Human genes 0.000 description 2
108090000790 Enzymes Proteins 0.000 description 2
101710154643 Filamentous hemagglutinin Proteins 0.000 description 2
206010016952 Food poisoning Diseases 0.000 description 2
208000019331 Foodborne disease Diseases 0.000 description 2
208000031886 HIV Infections Diseases 0.000 description 2
241000713772 Human immunodeficiency virus 1 Species 0.000 description 2
241000713340 Human immunodeficiency virus 2 Species 0.000 description 2
241001465754 Metazoa Species 0.000 description 2
241000588653 Neisseria Species 0.000 description 2
108091034117 Oligonucleotide Proteins 0.000 description 2
206010039438 Salmonella Infections Diseases 0.000 description 2
241000713311 Simian immunodeficiency virus Species 0.000 description 2
UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
108091081024 Start codon Proteins 0.000 description 2
241000607626 Vibrio cholerae Species 0.000 description 2
241000607734 Yersinia <bacteria> Species 0.000 description 2
JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 2
125000000539 amino acid group Chemical group 0.000 description 2
238000004458 analytical method Methods 0.000 description 2
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
210000003578 bacterial chromosome Anatomy 0.000 description 2
230000003115 biocidal effect Effects 0.000 description 2
238000005119 centrifugation Methods 0.000 description 2
210000000349 chromosome Anatomy 0.000 description 2
238000001514 detection method Methods 0.000 description 2
230000000688 enterotoxigenic effect Effects 0.000 description 2
230000002068 genetic effect Effects 0.000 description 2
238000011534 incubation Methods 0.000 description 2
238000003780 insertion Methods 0.000 description 2
230000037431 insertion Effects 0.000 description 2
238000013507 mapping Methods 0.000 description 2
244000005700 microbiome Species 0.000 description 2
229910052760 oxygen Inorganic materials 0.000 description 2
239000001301 oxygen Substances 0.000 description 2
229920001184 polypeptide Polymers 0.000 description 2
102000004196 processed proteins & peptides Human genes 0.000 description 2
230000001105 regulatory effect Effects 0.000 description 2
230000004044 response Effects 0.000 description 2
230000002441 reversible effect Effects 0.000 description 2
206010039447 salmonellosis Diseases 0.000 description 2
239000006228 supernatant Substances 0.000 description 2
239000000725 suspension Substances 0.000 description 2
229940118696 vibrio cholerae Drugs 0.000 description 2
LVSPDZAGCBEQAV-UHFFFAOYSA-N 4-chloronaphthalen-1-ol Chemical compound C1=CC=C2C(O)=CC=C(Cl)C2=C1 LVSPDZAGCBEQAV-UHFFFAOYSA-N 0.000 description 1
244000058084 Aegle marmelos Species 0.000 description 1
235000003930 Aegle marmelos Nutrition 0.000 description 1
229920001817 Agar Polymers 0.000 description 1
241000223836 Babesia Species 0.000 description 1
241000193738 Bacillus anthracis Species 0.000 description 1
101100404147 Bacillus subtilis (strain 168) nasE gene Proteins 0.000 description 1
241000588807 Bordetella Species 0.000 description 1
108010041397 CD4 Antigens Proteins 0.000 description 1
241000283707 Capra Species 0.000 description 1
229920000623 Cellulose acetate phthalate Polymers 0.000 description 1
241000282693 Cercopithecidae Species 0.000 description 1
241000242722 Cestoda Species 0.000 description 1
241000606153 Chlamydia trachomatis Species 0.000 description 1
241000709687 Coxsackievirus Species 0.000 description 1
239000003155 DNA primer Substances 0.000 description 1
102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
108090000204 Dipeptidase 1 Proteins 0.000 description 1
206010059866 Drug resistance Diseases 0.000 description 1
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
241000991587 Enterovirus C Species 0.000 description 1
229920003136 Eudragit® L polymer Polymers 0.000 description 1
229920003137 Eudragit® S polymer Polymers 0.000 description 1
108060002716 Exonuclease Proteins 0.000 description 1
208000007212 Foot-and-Mouth Disease Diseases 0.000 description 1
206010018612 Gonorrhoea Diseases 0.000 description 1
241000606790 Haemophilus Species 0.000 description 1
241000606768 Haemophilus influenzae Species 0.000 description 1
208000005176 Hepatitis C Diseases 0.000 description 1
208000009889 Herpes Simplex Diseases 0.000 description 1
241000282412 Homo Species 0.000 description 1
108010001336 Horseradish Peroxidase Proteins 0.000 description 1
241000701074 Human alphaherpesvirus 2 Species 0.000 description 1
241000430519 Human rhinovirus sp. Species 0.000 description 1
206010061598 Immunodeficiency Diseases 0.000 description 1
208000029462 Immunodeficiency disease Diseases 0.000 description 1
239000006142 Luria-Bertani Agar Substances 0.000 description 1
201000009906 Meningitis Diseases 0.000 description 1
241000204031 Mycoplasma Species 0.000 description 1
229910002651 NO3 Inorganic materials 0.000 description 1
241000244206 Nematoda Species 0.000 description 1
NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
IOVCWXUNBOPUCH-UHFFFAOYSA-M Nitrite anion Chemical compound [O-]N=O IOVCWXUNBOPUCH-UHFFFAOYSA-M 0.000 description 1
239000000020 Nitrocellulose Substances 0.000 description 1
108700026244 Open Reading Frames Proteins 0.000 description 1
101710160107 Outer membrane protein A Proteins 0.000 description 1
108090000854 Oxidoreductases Proteins 0.000 description 1
102000004316 Oxidoreductases Human genes 0.000 description 1
238000012408 PCR amplification Methods 0.000 description 1
241001631646 Papillomaviridae Species 0.000 description 1
201000005702 Pertussis Diseases 0.000 description 1
241000224016 Plasmodium Species 0.000 description 1
241000205160 Pyrococcus Species 0.000 description 1
241000711798 Rabies lyssavirus Species 0.000 description 1
108091007187 Reductases Proteins 0.000 description 1
241000702670 Rotavirus Species 0.000 description 1
241001138501 Salmonella enterica Species 0.000 description 1
241001354013 Salmonella enterica subsp. enterica serovar Enteritidis Species 0.000 description 1
241000293871 Salmonella enterica subsp. enterica serovar Typhi Species 0.000 description 1
241000700584 Simplexvirus Species 0.000 description 1
241000282887 Suidae Species 0.000 description 1
210000001744 T-lymphocyte Anatomy 0.000 description 1
108020005038 Terminator Codon Proteins 0.000 description 1
241000242541 Trematoda Species 0.000 description 1
239000007983 Tris buffer Substances 0.000 description 1
229920004890 Triton X-100 Polymers 0.000 description 1
241000607598 Vibrio Species 0.000 description 1
239000004480 active ingredient Substances 0.000 description 1
239000008272 agar Substances 0.000 description 1
239000003242 anti bacterial agent Substances 0.000 description 1
210000003719 b-lymphocyte Anatomy 0.000 description 1
201000008680 babesiosis Diseases 0.000 description 1
229940065181 bacillus anthracis Drugs 0.000 description 1
102000006635 beta-lactamase Human genes 0.000 description 1
230000004071 biological effect Effects 0.000 description 1
230000005540 biological transmission Effects 0.000 description 1
239000000872 buffer Substances 0.000 description 1
210000004899 c-terminal region Anatomy 0.000 description 1
239000000969 carrier Substances 0.000 description 1
210000004970 cd4 cell Anatomy 0.000 description 1
229920002301 cellulose acetate Polymers 0.000 description 1
229940081734 cellulose acetate phthalate Drugs 0.000 description 1
230000008859 change Effects 0.000 description 1
229940038705 chlamydia trachomatis Drugs 0.000 description 1
230000001276 controlling effect Effects 0.000 description 1
238000012937 correction Methods 0.000 description 1
101150105804 cysG gene Proteins 0.000 description 1
238000012217 deletion Methods 0.000 description 1
230000037430 deletion Effects 0.000 description 1
239000003085 diluting agent Substances 0.000 description 1
238000004520 electroporation Methods 0.000 description 1
239000002702 enteric coating Substances 0.000 description 1
238000009505 enteric coating Methods 0.000 description 1
239000000147 enterotoxin Substances 0.000 description 1
231100000655 enterotoxin Toxicity 0.000 description 1
208000028104 epidemic louse-borne typhus Diseases 0.000 description 1
102000013165 exonuclease Human genes 0.000 description 1
238000002474 experimental method Methods 0.000 description 1
239000013613 expression plasmid Substances 0.000 description 1
239000000284 extract Substances 0.000 description 1
238000009472 formulation Methods 0.000 description 1
230000002496 gastric effect Effects 0.000 description 1
-1 glycine amino acids Chemical class 0.000 description 1
229940047650 haemophilus influenzae Drugs 0.000 description 1
208000005252 hepatitis A Diseases 0.000 description 1
208000002672 hepatitis B Diseases 0.000 description 1
239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
230000007813 immunodeficiency Effects 0.000 description 1
230000005847 immunogenicity Effects 0.000 description 1
238000001727 in vivo Methods 0.000 description 1
208000015181 infectious disease Diseases 0.000 description 1
239000002198 insoluble material Substances 0.000 description 1
101150109249 lacI gene Proteins 0.000 description 1
201000004792 malaria Diseases 0.000 description 1
239000003550 marker Substances 0.000 description 1
239000000463 material Substances 0.000 description 1
230000007246 mechanism Effects 0.000 description 1
230000001404 mediated effect Effects 0.000 description 1
239000012528 membrane Substances 0.000 description 1
230000035772 mutation Effects 0.000 description 1
101150100899 nirC gene Proteins 0.000 description 1
101150045642 nirD gene Proteins 0.000 description 1
229920001220 nitrocellulos Polymers 0.000 description 1
244000052769 pathogen Species 0.000 description 1
230000001717 pathogenic effect Effects 0.000 description 1
239000000546 pharmaceutical excipient Substances 0.000 description 1
230000003389 potentiating effect Effects 0.000 description 1
230000002028 premature Effects 0.000 description 1
230000001737 promoting effect Effects 0.000 description 1
238000011321 prophylaxis Methods 0.000 description 1
230000001681 protective effect Effects 0.000 description 1
230000010076 replication Effects 0.000 description 1
230000000241 respiratory effect Effects 0.000 description 1
239000012723 sample buffer Substances 0.000 description 1
238000012163 sequencing technique Methods 0.000 description 1
210000002966 serum Anatomy 0.000 description 1
230000035939 shock Effects 0.000 description 1
235000017557 sodium bicarbonate Nutrition 0.000 description 1
229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
239000011780 sodium chloride Substances 0.000 description 1
238000000527 sonication Methods 0.000 description 1
241000894007 species Species 0.000 description 1
230000010473 stable expression Effects 0.000 description 1
238000010186 staining Methods 0.000 description 1
238000003756 stirring Methods 0.000 description 1
238000006467 substitution reaction Methods 0.000 description 1
108010044241 tetanus toxin fragment C Proteins 0.000 description 1
230000005030 transcription termination Effects 0.000 description 1
108091006106 transcriptional activators Proteins 0.000 description 1
230000002103 transcriptional effect Effects 0.000 description 1
LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
206010061393 typhus Diseases 0.000 description 1
241000712461 unidentified influenza virus Species 0.000 description 1
230000035899 viability Effects 0.000 description 1
230000003612 virological effect Effects 0.000 description 1
238000005406 washing Methods 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/1085—Transferases (2.) transferring alkyl or aryl groups other than methyl groups (2.5)
- C12N9/1088—Glutathione transferase (2.5.1.18)
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
- C07K2319/23—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a GST-tag
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/55—Fusion polypeptide containing a fusion with a toxin, e.g. diphteria toxin
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
- C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
- C07K2319/75—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Genetics & Genomics (AREA)
Engineering & Computer Science (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
Biomedical Technology (AREA)
Wood Science & Technology (AREA)
Zoology (AREA)
Biotechnology (AREA)
Molecular Biology (AREA)
General Engineering & Computer Science (AREA)
Microbiology (AREA)
Biochemistry (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Physics & Mathematics (AREA)
Biophysics (AREA)
Plant Pathology (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Peptides Or Proteins (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

SK99-96A 1994-01-31 1994-07-29 Vaccine preparations SK9996A3 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
GB9401787A GB9401787D0 (en)	1994-01-31	1994-01-31	Vaccine compositions
PCT/GB1994/001647 WO1995004151A2 (en)	1993-07-30	1994-07-29	Vaccine compositions containing recombinant tetc-fusion proteins

Publications (1)

Publication Number	Publication Date
SK9996A3 true SK9996A3 (en)	1996-09-04

Family

ID=10749593

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SK99-96A SK9996A3 (en)	1994-01-31	1994-07-29	Vaccine preparations

Country Status (7)

Country	Link
US (1)	US6488926B1 (cs)
KR (1)	KR100338894B1 (cs)
CZ (1)	CZ24196A3 (cs)
GB (1)	GB9401787D0 (cs)
HU (1)	HUT74495A (cs)
PL (1)	PL186847B1 (cs)
SK (1)	SK9996A3 (cs)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7214787B1 (en) *	1993-09-21	2007-05-08	United States Of America As Represented By The Secretary Of The Army	Recombinant vaccine against botulinum neurotoxin
GB0205376D0 (en) *	2002-03-07	2002-04-24	Royal Holloway University Of L	Spore germination
US20090110702A1 (en) *	2002-07-12	2009-04-30	The Johns Hopkins University	Mesothelin Vaccines and Model Systems and Control of Tumors
US9200036B2 (en)	2002-07-12	2015-12-01	The Johns Hopkins University	Mesothelin vaccines and model systems
US20050175625A1 (en) *	2002-07-12	2005-08-11	The Johns Hopkins University	Mesothelin vaccines and model systems
US7521059B2 (en) *	2004-06-14	2009-04-21	Fenwick Bradley W	Kennel cough vaccine
US7713737B2 (en) *	2004-10-04	2010-05-11	Trinity Biosystems, Inc.	Methods and compositions for needleless delivery of macromolecules
US7964200B2 (en)	2005-05-18	2011-06-21	Children's Hospital & Research Center At Oakland	Methods and compositions for immunizing against Chlamydia infection
US20090148401A1 (en) *	2005-12-05	2009-06-11	Trinity Biosystems, Inc.	Methods and compositions for needleless delivery of binding partners
US7666991B2 (en) *	2005-12-05	2010-02-23	Trinity Biosystems, Inc.	Compositions for needleless delivery of antibodies
EP2010205A2 (en) *	2006-03-16	2009-01-07	Trinity Biosystems, Inc.	Methods for increasing the size of animals using needleless delivery constructs
AU2007268684B2 (en) *	2006-05-31	2012-02-23	Toyama Chemical Co., Ltd.	Anti-foot-and-mouth disease virus agent for animal belonging to family Suidae or sheep, and method for prevention or treatment of foot-and-mouth disease in animal belonging to family Suidae or sheep
US20090092660A1 (en) *	2006-08-09	2009-04-09	Trinity Biosystems, Inc.	Methods and compositions for needleless delivery of particles
EP2373338B1 (en)	2008-12-03	2017-02-15	The Johns Hopkins University	Annexina2 as immunological target
US11246915B2 (en)	2010-09-15	2022-02-15	Applied Molecular Transport Inc.	Cholix toxin-derived fusion molecules for oral delivery of biologically active cargo
EP3139965B1 (en)	2014-05-07	2021-09-29	Applied Molecular Transport Inc.	Cholix toxin-derived fusion molecules for oral delivery of biologically active cargo
MX2022001975A (es)	2019-08-16	2022-03-11	Applied Molecular Transport Inc	Composiciones, formulaciones y produccion y purificacion de interleucinas.

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB8516442D0 (en) *	1985-06-28	1985-07-31	Wellcome Found	Cloned antigen
JP2921574B2 (ja)	1988-02-01	1999-07-19	アメリカン・サイアナミド・カンパニー	接合体ワクチンの担体分子としてのｔ細胞のエピトープ
GB8914122D0 (en) *	1989-06-20	1989-08-09	Wellcome Found	Polypeptide expression
CA2031468A1 (en)	1989-12-08	1991-06-09	Mitchell S. Gross	Malaria vaccine
FR2656626B1 (fr)	1989-12-29	1994-08-12	Pasteur Institut	Fragment peptidique comprenant une sequence issue de la proteine 28 kda de schistosoma mansoni et compositions vaccinantes et/ou therapeutiques comprenant ledit fragment.
US5498538A (en) *	1990-02-15	1996-03-12	The University Of North Carolina At Chapel Hill	Totally synthetic affinity reagents
SK55593A3 (en)	1991-03-05	1993-10-06	Wellcome Found	Expresion of recombinant proteins in attenuated bacteria
SE468050C (sv) *	1991-03-15	1998-04-27	Pharmacia & Upjohn Ab	Rekombinant derivat av human faktor VIII
AU2699192A (en)	1991-10-16	1993-05-21	University Of Saskatchewan	Enhanced immunogenicity using leukotoxin chimeras
CA2141427C (en)	1992-07-31	2008-07-22	Mohammed Anjam Khan	Expression of recombinant fusion proteins in attenuated bacteria

1994
- 1994-01-31 GB GB9401787A patent/GB9401787D0/en active Pending
- 1994-07-29 PL PL94313979A patent/PL186847B1/pl not_active IP Right Cessation
- 1994-07-29 CZ CZ96241A patent/CZ24196A3/cs unknown
- 1994-07-29 HU HU9600207A patent/HUT74495A/hu unknown
- 1994-07-29 KR KR1019960700478A patent/KR100338894B1/ko not_active Expired - Fee Related
- 1994-07-29 SK SK99-96A patent/SK9996A3/sk unknown
- 1994-07-29 US US08/586,740 patent/US6488926B1/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
GB9401787D0 (en)	1994-03-23
PL313979A1 (en)	1996-08-05
KR100338894B1 (ko)	2002-11-13
US6488926B1 (en)	2002-12-03
CZ24196A3 (en)	1996-06-12
HU9600207D0 (en)	1996-04-29
PL186847B1 (pl)	2004-03-31
HUT74495A (en)	1997-01-28

Publication	Publication Date	Title
WO1995004151A2 (en)	1995-02-09	Vaccine compositions containing recombinant tetc-fusion proteins
US6488926B1 (en)	2002-12-03	Vaccine compositions
AU2018281889B2 (en)	2022-03-03	Recombinant measles virus expressing Zika virus proteins and their applications
AU2019203955B2 (en)	2021-02-18	Multipartite signaling proteins and uses thereof
CN111733290A (zh)	2020-10-02	一种检测新型冠状病毒及近缘冠状病毒的试剂盒及其制备方法
CN111440801A (zh)	2020-07-24	用于靶向敲除人NKG2A/KLRC1基因的sgRNA、表达载体、试剂盒及其应用
CN111662884A (zh)	2020-09-15	一种假病毒及其包装方法和药物评估系统
CN114164114B (zh)	2022-12-13	弓形虫核酮糖-5-磷酸异构酶TgRPI基因编辑虫株及其应用
CN108395996A (zh)	2018-08-14	一种猪瘟病毒亚单位疫苗及其制备方法和用途
CN112300952B (zh)	2023-05-09	一种产α-蒎烯的解脂耶氏酵母基因工程菌及其应用
CN109863166A (zh)	2019-06-07	具有降低的葡萄糖脱氢酶活性的产生鼠李糖脂的细胞
CN113717913A (zh)	2021-11-30	螺旋藻中的靶向诱变
CN109843909A (zh)	2019-06-04	利用替代的葡萄糖转运蛋白产生鼠李糖脂的细胞和方法
CN117083389A (zh)	2023-11-17	植物叶绿体胞嘧啶碱基编辑器与线粒体胞嘧啶碱基编辑器
CN112626266A (zh)	2021-04-09	新型冠状病毒SARS-CoV-2的检测引物组及应用
CN113046255B (zh)	2023-08-01	大规模基因重排的酵母菌及其构建方法
US6740323B1 (en)	2004-05-25	HBV/HCV virus-like particle
CN110225765B (zh)	2024-03-12	减毒猪流感疫苗以及其制备和使用方法
AU2017214373A1 (en)	2018-08-09	Methods and compositions for controlling ants
KR102093495B1 (ko)	2020-03-26	C형 간염 바이러스에 대한 키메라 백신 항원
KR20150100606A (ko)	2015-09-02	아테리바이러스 단백질 및 발현 메커니즘
CN101875692A (zh)	2010-11-03	中国仓鼠凋亡相关基因
CN117222664A (zh)	2023-12-12	用于破坏自身耐受的疫苗组合物
CN114774469B (zh)	2022-11-08	一种adcc功能增强的nk细胞的制作方法、nk细胞及其组合物
CN111337676A (zh)	2020-06-26	用于诊断自身免疫性胃炎的方法